Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Preferred Stock Liabilities (2020 - 2023)

Mimedx's Preferred Stock Liabilities history spans 4 years, with the latest figure at $92.5 million for Q3 2023.

  • For Q3 2023, Preferred Stock Liabilities changed 0.0% year-over-year to $92.5 million; the TTM value through Sep 2023 reached $92.5 million, changed 0.0%, while the annual FY2022 figure was $92.5 million, 0.0% changed from the prior year.
  • Preferred Stock Liabilities for Q3 2023 was $92.5 million at Mimedx, roughly flat from $92.5 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $92.5 million in Q2 2021 and bottomed at $91.1 million in Q3 2020.
  • The 4-year median for Preferred Stock Liabilities is $92.5 million (2021), against an average of $92.3 million.
  • The largest annual shift saw Preferred Stock Liabilities grew 1.52% in 2021 before it changed 0.0% in 2022.
  • A 4-year view of Preferred Stock Liabilities shows it stood at $91.6 million in 2020, then grew by 1.01% to $92.5 million in 2021, then changed by 0.0% to $92.5 million in 2022, then changed by 0.0% to $92.5 million in 2023.
  • Per Business Quant, the three most recent readings for MDXG's Preferred Stock Liabilities are $92.5 million (Q3 2023), $92.5 million (Q2 2023), and $92.5 million (Q1 2023).